{{chembox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 443978959
| ImageFile = Enzastaurin.png
| ImageSize = 180px
| IUPACName = 3-(1-Methylindol-3-yl)-4-[1-[1-(pyridin-2-ylmethyl)piperidin-4-yl]indol-3-yl]pyrrole-2,5-dione
| OtherNames = LY-317615
|Section1={{Chembox Identifiers
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = UC96G28EQF
| IUPHAR_ligand = 5693
| CASNo_Ref = {{cascite|correct|??}}
| CASNo = 170364-57-5
| PubChem = 176167
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 300138
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 153463
| SMILES = O=C3C(\c2c1ccccc1n(c2)C)=C(/C(=O)N3)c5c4ccccc4n(c5)C7CCN(Cc6ncccc6)CC7
| InChI = 1/C32H29N5O2/c1-35-19-25(23-9-2-4-11-27(23)35)29-30(32(39)34-31(29)38)26-20-37(28-12-5-3-10-24(26)28)22-13-16-36(17-14-22)18-21-8-6-7-15-33-21/h2-12,15,19-20,22H,13-14,16-18H2,1H3,(H,34,38,39)
| InChIKey = AXRCEOKUDYDWLF-UHFFFAOYAP
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C32H29N5O2/c1-35-19-25(23-9-2-4-11-27(23)35)29-30(32(39)34-31(29)38)26-20-37(28-12-5-3-10-24(26)28)22-13-16-36(17-14-22)18-21-8-6-7-15-33-21/h2-12,15,19-20,22H,13-14,16-18H2,1H3,(H,34,38,39)
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = AXRCEOKUDYDWLF-UHFFFAOYSA-N
}}
|Section2={{Chembox Properties
| C=32 | H=29 | N=5 | O=2 
| Appearance = 
| Density = 
| MeltingPt = 
| BoilingPt = 
| Solubility = }}
|Section3={{Chembox Hazards
| MainHazards = 
| FlashPt = 
| AutoignitionPt = }}
}}

'''Enzastaurin''' is a synthetic [[bisindolylmaleimide]] with potential [[antineoplastic]] activity. Binding to the ATP-binding site, enzastaurin selectively inhibits [[Protein kinase|protein kinase C]] beta, an enzyme involved in the induction of [[vascular endothelial growth factor]] (VEGF)-stimulated neo-angiogenesis. This agent may decrease tumor blood supply, preventing growth.

In 2013 it failed a phase III clinical trial for [[lymphoma]].<ref name=GE2013>[http://www.genengnews.com/gen-news-highlights/lilly-halts-development-of-lymphoma-drug-after-phase-iii-failure/81248350/ Lilly Halts Development of Lymphoma Drug After Phase III Failure]</ref>

==References==
{{reflist}}

==External links==
* [https://web.archive.org/web/20081005071319/http://www.nci.nih.gov/Templates/drugdictionary.aspx?CdrID=269069 Enzastaurin hydrochloride], National Institutes of Health


[[Category:Pyridines]]
[[Category:Piperidines]]
[[Category:Bisindolylmaleimides]]